-
1
المؤلفون: Mark-David Levin, Sabina Kersting, Julie M.N. Dubois, Yvette Norden, Johan A Dobber, Yvonne W.S. Jauw, Anne-Marie van der Kevie-Kersemaekers, Clemens Mellink, Koen de Heer, Leonie van der Burg, Doreen Te Raa, Fransien de Boer, Jolanda Droogendijk, Cecile Idink, Marten R. Nijziel, Lidwine W. Tick, Inge Ludwig, Matthijs Silbermann, Aart Beeker, Mar Bellido, Ludo M. Evers, Gerben JC Zwezerijnen, Carsten U Niemann, Arnon P. Kater
المصدر: Blood. 140:4137-4139
مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ed1625ac71a83ac6d32654e613af2049
https://doi.org/10.1182/blood-2022-163209 -
2
المؤلفون: Sabina Kersting, Julie Dubois, Kazem Nasserinejad, Johan A Dobber, Clemens Mellink, Anne-Marie F van der Kevie-Kersemaekers, Ludo M Evers, Fransien de Boer, Harry R Koene, John Schreurs, Marjolein van der Klift, Gerjo A Velders, Ellen van der Spek, Hanneke M van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F M Posthuma, Hein P J Visser, Ilse Houtenbos, Cecile A M Idink, Djamila E Issa, Ellen C Dompeling, Henk C T van Zaanen, Hendrik Veelken, Henriette Levenga, Lidwine W Tick, Wim E Terpstra, Sanne H Tonino, Michelle Boyer, Mehrdad Mobasher, Mark-David Levin, Arnon P Kater
المساهمون: Human Genetics, ARD - Amsterdam Reproduction and Development, Clinical Haematology, AII - Cancer immunology, CCA - Cancer Treatment and Quality of Life, Experimental Immunology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), Hematology
المصدر: The Lancet Haematology, 9(3), e190-e199. Lancet Publishing Group
The Lancet Haematology, 9(3), E190-E199. ELSEVIER SCI LTDمصطلحات موضوعية: Male, Sulfonamides, Adolescent, FLOW, MINIMAL RESIDUAL DISEASE, Hematology, QUANTIFICATION, Antibodies, Monoclonal, Humanized, Bridged Bicyclo Compounds, Heterocyclic, GUIDELINES, DIAGNOSIS, Leukemia, Lymphocytic, Chronic, B-Cell, MRD, CHLORAMBUCIL, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, RITUXIMAB, CLL
وصف الملف: application/pdf
-
3دورية أكاديمية
المؤلفون: Arnon P. Kater, Marinus H.J. van Oers, Yvette van Norden, Lina van der Straten, Julia Driessen, Ward F.M. Posthuma, Martin Schipperus, Martine E.D. Chamuleau, Marcel Nijland, Jeanette K. Doorduijn, Michel Van Gelder, Mels Hoogendoorn, Francien De Croon, Shulamiet Wittebol, J. Martijn Kerst, Erik W.A. Marijt, Reinier A.P. Raymakers, Martijn R. Schaafsma, Johan A. Dobber, Sabina Kersting, Mark-David Levin
المصدر: Haematologica, Vol 104, Iss 1 (2019)
مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5
وصف الملف: electronic resource
-
4
المؤلفون: Arnon P Kater, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J Veldhuis, Rogier Mous, Clemens H M Mellink, Anne-Marie F van der Kevie-Kersemaekers, Johan A Dobber, Christian B Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa T T Tran, Kazem Nasserinejad, Carsten U Niemann
المساهمون: Hematology, Experimental Immunology, Clinical Haematology, CCA - Cancer Treatment and Quality of Life, Human Genetics, ARD - Amsterdam Reproduction and Development
المصدر: The Lancet Oncology, 23(6), 818-828. Lancet Publishing Group
Kater, A P, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, van der Kevie-Kersemaekers, A-M F, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Brieghel, C, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Niemann, C U 2022, ' Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION) : primary analysis of an open-label, randomised, phase 2 trial ', The Lancet Oncology, vol. 23, no. 6, pp. 818-828 . https://doi.org/10.1016/S1470-2045(22)00220-0
Lancet Oncology, 23(6), 818-828. ELSEVIER SCIENCE INC
The Lancet. Oncology, 23(6), 818-828. Lancet Publishing Groupمصطلحات موضوعية: Sulfonamides, BCL2, Neoplasm, Residual, Adenine, PROLIFERATION, MULTICENTER, Bridged Bicyclo Compounds, Heterocyclic, BCR, Leukemia, Lymphocytic, Chronic, B-Cell, 1ST-LINE TREATMENT, Pyrimidines, Piperidines, Oncology, Antineoplastic Combined Chemotherapy Protocols, CYCLOPHOSPHAMIDE, CELLS, Humans, Pyrazoles, RITUXIMAB, FLUDARABINE, CLL
وصف الملف: application/pdf
-
5
المؤلفون: Mark-David Levin, Julie Dubois, Rogier Mous, Ellen C Dompeling, Hoa T. T. Tran, Mar Bellido, Christian Bjørn Poulsen, Juha Ranti, Sabina Kersting, Ida Schjødt, Arnon P. Kater, Ann Janssens, Henrik Frederiksen, Clemens Mellink, Johan A. Dobber, Mattias Mattsson, Carsten Utoft Niemann, Lisbeth Enggaard, Gerrit J Veldhuis, Kazem Nasserinejad
المساهمون: Hematology, Human Genetics, AII - Cancer immunology, Experimental Immunology, Clinical Haematology, CCA - Cancer Treatment and Quality of Life
المصدر: Blood, 137(8), 1117-1120. AMER SOC HEMATOLOGY
Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608
Blood, 137(8), 1117-1120. American Society of Hematology
Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608مصطلحات موضوعية: Oncology, medicine.medical_specialty, Science & Technology, Venetoclax, business.industry, Chronic lymphocytic leukemia, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, 1ST-LINE TREATMENT, chemistry.chemical_compound, chemistry, Ibrutinib, Internal medicine, Relapsed refractory, medicine, RITUXIMAB, business, Life Sciences & Biomedicine
وصف الملف: application/pdf; Print
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdc9ad8a3176dac8f8c391574fbbaa55
https://hdl.handle.net/11370/98d01a12-fd30-4fee-916b-cdd713c9d5b3 -
6
المؤلفون: Rebecka Svanberg, Rogier Mous, Mattias Mattson, Arnon P. Kater, Sabina Kersting, Hoa T. T. Tran, Kazem Nasserinejad, Carsten Utoft Niemann, Sisse R. Ostrowski, Johan A. Dobber, Mark-David Levin
المساهمون: Experimental Immunology, Clinical Haematology, CCA - Cancer Treatment and Quality of Life, Hematology
المصدر: Leukemia & lymphoma, 61(14), 3422-3431. Informa Healthcare
Leukemia and Lymphoma, 61(14), 3422-3431. Informa Healthcareمصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Combination therapy, Chronic lymphocytic leukemia, medicine.medical_treatment, Targeted therapy, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Piperidines, SDG 3 - Good Health and Well-being, ibrutinib, Internal medicine, Humans, Medicine, Adverse effect, Sulfonamides, medicine.diagnostic_test, venetoclax, business.industry, Venetoclax, Adenine, Hematology, Bridged Bicyclo Compounds, Heterocyclic, medicine.disease, bleeding, targeted therapy, Leukemia, Lymphocytic, Chronic, B-Cell, Thromboelastography, chemistry, 030220 oncology & carcinogenesis, Hemostasis, Ibrutinib, hemostasis, business, CLL, 030215 immunology
-
7
المؤلفون: Mels Hoogendoorn, Ellen van der Spek, Clemens Mellink, Fransien Croon-de Boer, Julie Dubois, Shulamiet Wittebol, Mehrdad Mobasher, Sanne H. Tonino, Arnon P. Kater, Mark-David Levin, John Schreurs, Cecile Idink, Hein Visser, Yvette van Norden, Sabina Kersting, L. M. Evers, Johan A. Dobber
المساهمون: Hematology, Experimental Immunology, Clinical Haematology, CCA - Cancer Treatment and Quality of Life, Human Genetics
المصدر: Blood advances, 2(24), 3566-3571. American Society of Hematology
مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Neoplasm, Residual, Randomization, Clinical Trials and Observations, Chronic lymphocytic leukemia, Population, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, Obinutuzumab, hemic and lymphatic diseases, Internal medicine, medicine, Humans, education, Aged, Sulfonamides, education.field_of_study, business.industry, Venetoclax, Remission Induction, Hematology, Middle Aged, Bridged Bicyclo Compounds, Heterocyclic, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Minimal residual disease, body regions, Tumor lysis syndrome, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Monoclonal, Drug Therapy, Combination, Female, Tumor Lysis Syndrome, business
-
8
المؤلفون: Karima Amaador, Josephine M. I. Vos, Steven T. Pals, Willem Kraan, Johan A. Dobber, Monique C. Minnema, Harry R. Koene, Peter C. de Bruin, Aiko H. Zwinderman, Marie José Kersten
المساهمون: Hematology, Graduate School, Clinical Haematology, General Internal Medicine, AII - Cancer immunology, CCA - Cancer biology and immunology, Pathology, 09 Laboratory specialisms, Epidemiology and Data Science, APH - Methodology, CCA - Cancer Treatment and Quality of Life
المصدر: Amaador, K, Vos, J M I, Pals, S T, Kraan, W, Dobber, J A, Minnema, M C, Koene, H R, de Bruin, P C, Zwinderman, A H & Kersten, M J 2022, ' Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression ', Leukemia and Lymphoma, vol. 63, no. 5, pp. 1070-1079 . https://doi.org/10.1080/10428194.2021.2018584
Leukemia and Lymphoma, 63(5), 1070-1079. Informa Healthcare
Leukemia & lymphoma. Informa Healthcareمصطلحات موضوعية: Cancer Research, Oncology, Waldenström’s macroglobulinemia, Bone Marrow, Mutation, Myeloid Differentiation Factor 88, Humans, Hematology, Lymphoma, B-Cell, Marginal Zone, Waldenstrom Macroglobulinemia, LASSO regression, marginal zone lymphoma, Immunophenotyping
-
9
المؤلفون: Harry R. Koene, Lina van der Straten, J. Martijn Kerst, Sabina Kersting, Arnon P. Kater, Reinier Raymakers, Fatemeh Saberi Hosnijeh, Anton W. Langerak, Mark-David Levin, Mar Bellido, Martijn R. Schaafsma, G. Doreen te Raa, Martine E.D. Chamuleau, Jeanette K. Doorduijn, Marinus H. J. van Oers, Mels Hoogendoorn, Erik W.A. Marijt, Ward Posthuma, Sanne H. Tonino, Fransien de Boer, Michel van Gelder, Johan A. Dobber
المساهمون: IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Experimental Immunology, Clinical Haematology, AII - Cancer immunology, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Immunology, Hematology, VU University medical center
المصدر: Experimental Hematology, 89, 55. Elsevier
Experimental hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60. ELSEVIER SCIENCE INC
Experimental Hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60.e6. ELSEVIER SCIENCE INC
Saberi Hosnijeh, F, van der Straten, L, Kater, A P, van Oers, M H J, Posthuma, W F M, Chamuleau, M E D, Bellido, M, Doorduijn, J K, van Gelder, M, Hoogendoorn, M, de Boer, F, te Raa, G D, Kerst, J M, Marijt, E W A, Raymakers, R A P, Koene, H R, Schaafsma, M R, Dobber, J A, Tonino, S H, Kersting, S S, Langerak, A W & Levin, M-D 2020, ' Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study ', Experimental Hematology, vol. 89, pp. 55-60.e6 . https://doi.org/10.1016/j.exphem.2020.08.002مصطلحات موضوعية: Male, Proteomics, 0301 basic medicine, Oncology, Cancer Research, Chronic lymphocytic leukemia, Gene Expression, 0302 clinical medicine, STAGE, hemic and lymphatic diseases, Stage (cooking), Lenalidomide, Chemo immunotherapy, Aged, 80 and over, RISK, Hematology, Middle Aged, Prognosis, Treatment Outcome, 030220 oncology & carcinogenesis, MATRIPTASE, Female, Immunotherapy, Immunoglobulin Heavy Chains, Rituximab, EXPRESSION, medicine.medical_specialty, Treatment response, Proteinase Inhibitory Proteins, Secretory, Antineoplastic Agents, Disease-Free Survival, 03 medical and health sciences, Signaling Lymphocytic Activation Molecule Family, Internal medicine, Biomarkers, Tumor, Genetics, medicine, Humans, SOLUBLE CD23, Molecular Biology, Aged, Receptors, IgE, business.industry, Cell Biology, Serum samples, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Tumor Necrosis Factor Receptor Superfamily, Member 7, 030104 developmental biology, Mutation, Immunoglobulin heavy chain, Chlorambucil, business
وصف الملف: application/pdf
-
10
المؤلفون: Kazem Nasserinejad, Juha Ranti, Clemens Mellink, Carsten Utoft Niemann, Christian Bjørn Poulsen, Johan A. Dobber, Ann Janssens, Mark-David Levin, Henrik Frederiksen, Ellen C Dompeling, Rogier Mous, Arnon P. Kater, Ida Schjødt, Julie Dubois, Hoa T Tran, Sabina Kersting, Lisbeth Enggaard, Gerrit J Veldhuis, Mattias Mattsson, Mar Bellido
المصدر: Niemann, C U, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Juha Ranti, J, Mattsson, M, Bellido, M, Tran, H T, Nasserinejad, K, Levin, M-D & Kater, A P 2019, ' Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) – 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial ', Blood, vol. 134, no. Supplement 1, 4292 . https://doi.org/10.1182/blood-2019-124377
Niemann, C U, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Juha Ranti, J, Mattsson, M, Bellido, M, Tran, H T, Nasserinejad, K, Levin, M-D & Kater, A P 2019, ' Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) – 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial ', American Society of Hematology: 61st Annual Meeting (ASH), Orlando, United States, 07/12/2019-10/12/2019 . < https://ashpublications.org/blood/article/134/Supplement_1/4292/425636/Venetoclax-and-Ibrutinib-for-Patients-with >
University of Southern Denmarkمصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Immunology, Population, Biochemistry, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Maintenance therapy, Obinutuzumab, Internal medicine, medicine, education, health care economics and organizations, education.field_of_study, Intention-to-treat analysis, business.industry, Venetoclax, Cell Biology, Hematology, Interim analysis, Regimen, 030104 developmental biology, chemistry, Ibrutinib, business, 030215 immunology
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e2ac4db43bb467b60fdbf45c2ca0499
https://portal.findresearcher.sdu.dk/da/publications/c67d35ca-bdfc-4af4-986b-fb9216884683
Full Text via ClinicalKey 
Full Text Finder 
PDF full text from Publisher